ESC Premium Access

Age and extent of coronary artery disease are associated with complexity of induced atrial fibrillation

Presentation

About the speaker

Doctor Elton Dudink

Maastricht University Medical Centre (MUMC), Maastricht (Netherlands (The))
0 follower

53 more presentations in this session

Differences between randomized controlled clinical trials and real-world atrial fibrillation patients treated with oral anticoagulants - do we treat the same patients? Results from the CRAFT study

Speaker: Doctor A. Tyminska (Warsaw, PL)

Thumbnail

Which factors influence the choice of a non-vitamin K oral anticoagulant over warfarin for stroke prevention among atrial fibrillation patients? Insights from the prospective SPRINT-AF registry.

Speaker: Doctor M. Gupta (Toronto, CA)

Thumbnail

Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in germany - insights from the reload study

Speaker: Professor H. Bonnemeier (Kiel, DE)

Thumbnail

Increased thromboprophylactic treatment of patients with atrial fibrillation after the introduction of NOACs - an analysis of sex and gender differences

Speaker: Ms D. Loikas (Stockholm, SE)

Thumbnail

Comparison of stroke- and bleed-related healthcare resource utilization (HCRU) among patients with non-valvular atrial fibrillation (NVAF), newly treated with oral anti-coagulants (OACs)

Speaker: Doctor J. Franchino-Elder (Ridgefield, US)

Thumbnail

Access the full session

Poster session 4 - Stroke prevention

Speakers: Doctor E. Dudink, Doctor A. Tyminska, Doctor M. Gupta, Professor H. Bonnemeier, Ms D. Loikas...
Thumbnail

About the event

Image

ESC CONGRESS 2017

26 August - 30 August 2017

Sessions Presentations

This platform is supported by

logo Novo Nordisk